Low-fluence Q-switched neodymium-doped yttrium aluminum garnet laser for melasma with pre- or post-treatment triple combination cream

Dermatol Surg. 2010 Jun;36(6):909-18. doi: 10.1111/j.1524-4725.2010.01523.x. Epub 2010 Apr 1.

Abstract

Background: Topical triple combination (TC) treatment is considered the primary approach to melasma. Recently, collimated low-fluence 1,064-nm Q-switched neodymium-doped yttrium aluminum garnet (Nd:YAG) laser treatment has attracted attention as an alternative approach.

Objectives: To compare the clinical efficacy and adverse effects of low-fluence Q-switched Nd:YAG laser when performed before and after treatment with topical TC using a split-face crossover design.

Methods: Thirteen patients with melasma received topical treatment with TC cream or 1,064-nm Q-switched Nd:YAG laser treatment on opposite sides of the face for 8 weeks, and then treatments were reversed for 8 weeks. Responses were evaluated using the Melasma Area and Severity Index scoring system, spectrophotometry measurements, and a subjective self-assessment method.

Results: After 16 weeks, better results were seen in subjective assessments when laser treatment was used after 8 weeks of topical TC treatment than before usage of TC. There were no significant adverse effects with the laser treatments.

Conclusions: Laser treatment after topical TC cream was found to be safer and more effective than the post-treatment use of topical agents.

Publication types

  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Administration, Topical
  • Adult
  • Antioxidants / administration & dosage
  • Combined Modality Therapy
  • Cross-Over Studies
  • Drug Administration Schedule
  • Drug Combinations
  • Female
  • Fluocinolone Acetonide / administration & dosage*
  • Glucocorticoids / administration & dosage
  • Humans
  • Hydroquinones / administration & dosage*
  • Keratolytic Agents / administration & dosage
  • Lasers, Solid-State / therapeutic use*
  • Male
  • Melanosis / drug therapy*
  • Melanosis / pathology
  • Melanosis / surgery*
  • Middle Aged
  • Treatment Outcome
  • Tretinoin / administration & dosage*

Substances

  • Antioxidants
  • Drug Combinations
  • Glucocorticoids
  • Hydroquinones
  • Keratolytic Agents
  • Fluocinolone Acetonide
  • Tretinoin
  • hydroquinone